Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
|Articles|October 27, 2012
Researchers on Wavefront Optics, Central Vision Loss Earn Professional Awards
Larry N. Thibos, PhD, FAAO, and Susana T.L. Chung, OD, PhD, FAAO, received the Charles F. Prentice Medal and the Glenn A. Fry Award, respectively, during the annual awards ceremony at the 2012 American Academy of Optometry meeting.
Advertisement
Advertisement
Related to this article
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5